Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era

Seyoung Seo, Jung Yong Hong, Shinkyo Yoon, Changhoon Yoo, Ji Hyun Park, Jung Bok Lee, Chan Sik Park, Jooryung Huh, Yoonse Lee, Kyung Won Kim, Jin Sook Ryu, Seok Jin Kim, Won Seog Kim, Dok Hyun Yoon, Cheolwon Suh

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

The prognostic value of serum beta-2 microglobulin for diffuse large B-cell lymphoma (DLBCL) is not well known in the rituximab era. A retrospective registry data analysis of 833 patients with de novo DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) was conducted to establish the prognostic significance of serum beta-2 microglobulin at a ≥ 2.5 mg/L cutoff. Five-year progression-free survival (PFS, 76.1% vs. 41.0%; p < 0.001) and overall survival (OS, 83.8% vs. 49.2%; p < 0.001) were significantly worse in patients with elevated serum beta-2 microglobulin (n = 290, 34.8%). Furthermore, the five parameters of the International Prognostic Index, accompanying B symptoms, bone marrow involvement and impaired renal function were associated with worse PFS and OS. In multivariate analysis, elevated beta-2 microglobulin was a significant poor prognostic factor for PFS (hazard ratio [HR], 1.70; 95% confidence interval [CI], 1.29-2.24; p < 0.001) and OS (HR, 2.0; 95% CI, 1.47-2.75; p < 0.001). In an independent validation cohort of 258 R-CHOP treated patients with de novo DLBCL, elevated beta-2 microglobulin levels remained a significant poor prognostic factor for PFS (HR, 2.03; 95% CI, 1.23-3.32; p = 0.005) and exhibited a strong trend of association with worse OS (HR, 1.64; 95% CI, 0.98-2.75; p = 0.062). The significance of serum beta-2 microglobulin levels as an independent prognostic factor for patients with DLBCL receiving R-CHOP is confirmed.

Original languageEnglish (US)
Pages (from-to)76934-76943
Number of pages10
JournalOncotarget
Volume7
Issue number47
DOIs
StatePublished - 2016

Keywords

  • Beta 2-microglobulin
  • Diffuse large B-cell lymphoma
  • Non-Hodgkin lymphoma
  • Prognosis
  • Rituximab

Fingerprint Dive into the research topics of 'Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era'. Together they form a unique fingerprint.

Cite this